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Learning objectives
 ► Around one half of angina patients have no 
obstructive coronary disease; many of these 
patients have microvascular and/or vasospastic 
angina.
 ► Tests of coronary artery function empower 
clinicians to make a correct diagnosis (rule- in/
rule- out), complementing coronary angiography.
 ► Physician and patient education, lifestyle, 
medications and revascularisation are key 
aspects of management.
InTroduCTIon
Ischaemic heart disease (IHD) remains the leading 
global cause of death and lost life years in adults, 
notably in younger (<55 years) women.1 Angina 
pectoris (derived from the Latin verb ‘angere’ to 
strangle) is chest discomfort of cardiac origin. It is a 
common clinical manifestation of IHD with an esti-
mated prevalence of 3%–4% in UK adults. There 
are over 250 000 invasive coronary angiograms 
performed each year with over 20 000 new cases of 
angina. The healthcare resource utilisation is appre-
ciable with over 110 000 inpatient episodes each 
year leading to substantial associated morbidity.2 In 
1809, Allen Burns (Lecturer in Anatomy, Univer-
sity of Glasgow) developed the thesis that myocar-
dial ischaemia (supply:demand mismatch) could 
explain angina, this being first identified by William 
Heberden in 1768. Subsequent to Heberden’s 
report, coronary artery disease (CAD) was impli-
cated in pathology and clinical case studies under-
taken by John Hunter, John Fothergill, Edward 
Jenner and Caleb Hiller Parry.3 Typically, angina 
involves a relative deficiency of myocardial oxygen 
supply (ie, ischaemia) and typically occurs after 
activity or physiological stress (box 1).
Six decades have passed since the first reported 
invasive coronary angiogram; however, many 
physicians still consider detecting obstructive 
epicardial CAD on coronary angiography a ‘sine 
qua non’ for the diagnosis of angina.4 The detec-
tion of obstructive CAD allows evidence- based 
medical treatment and consideration of myocar-
dial revascularisation. However, underlying patho-
physiology is more nuanced with contributions 
from anatomical atherosclerotic and/or functional 
alterations of epicardial vessels and/or microcir-
culation (figure 1).5 ESC guidelines6 have revised 
nomenclature (‘Chronic Coronary Syndromes’) in 
part reflecting the importance of patients with signs 
and symptoms of ischaemia without obstructive 
coronary artery disease—INOCA.7 8 Around half of 
all patients with angina undergoing elective coro-
nary angiography have no obstructive epicardial 
CAD.9 This large, heterogeneous chronic coronary 
syndrome is comprised of distinct vasomotor disor-
ders including microvascular angina (MVA) and/or 
vasospastic angina (VSA)—the two most common 
underlying disorders of coronary vascular function 
in the INOCA population. Crucially, we stress that 
there are often multiple mechanisms of myocardial 
ischaemia occurring in various coronary compart-
ments via different mechanisms. These frequently 
coexist in combination; however, an appreciation 
of this fact can help stratify treatment and help us 
understand patients with poor treatment response 
(eg, angina after revascularisation).
We begin by classifying angina according to patho-
physiology. We then consider the current guidelines 
and their strengths and limitations for assessing 
patients with recent onset of stable chest pain. We 
review non- invasive and invasive functional tests of 
the coronary circulation with linked management 
strategies. Finally, we point to future directions 
providing hope for improved patient outcomes and 
development of targeted disease- modifying therapy. 
The aim of this educational review is to provide a 
contemporary approach to diagnosis and manage-
ment of angina taking into consideration epicardial 
coronary disease, microcirculatory dysfunction and 
coronary vasospasm.
ConTEmporary angIna CLassIfICaTIon by 
paTHopHysIoLogy
The clinical history is of paramount importance 
to initially establish whether the nature of the 
presenting symptoms is consistent with angina 
(box 1). Indeed, recent data supports specialist 
physicians under- recognise angina in up to half of 
their patients.10 Furthermore, contemporary clinical 
trials of revascularisation in stable IHD including 
the ISCHEMIA trial highlight the importance of 
good clinical history and listening to our patients to 
determine the nature and frequency of symptoms 
which helps to plan management. We propose a 
classification of angina that aligns with underlying 
aetiology and related management (table 1).
angina with obstructive coronary artery disease
2018 ESC guidelines on myocardial revascularisa-
tion define obstructive CAD as coronary stenosis 
with documented ischaemia, a haemodynamically 
relevant lesion (ie, fractional flow reserve (FFR) 
≤0.80 or  non- hyperaemic  pressure  ratio  (NHPR) 
(eg,  iwFR≤0.89))  or  >90%  stenosis  in  a  major 
coronary vessel (table 1). There is renewed interest 
in NHPRs (iwFR, resting full- cycle ratio (RFR) and 
diastolic pressure ratio (dPR)) as data have emerged 
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box 1 definition of angina (nICE guidelines)32
Typical angina: (requires all three)
1. Constricting discomfort in the front of the chest or in the neck, shoulders, 
jaw or arms.
2. Precipitated by physical exertion.
3. Relieved by rest or sublingual glyceryl trinitrate within about 5 min
 – Presence of two of the features is defined as atypical angina.
 – Presence of one or none of the features is defined as non- anginal chest 
pain.
 – Stable angina may be excluded if pain is non- anginal provided clinical 
suspicion is not raised based on other aspects of the history and risk 
factors.
 – Do not define typical, atypical and non- anginal chest pain differently in 
men and women or different ethnic groups.
figure 1 Reappraisal of ischaemic heart disease pathophysiology. Distinct functional and structural mechanisms can affect coronary vascular 
function and frequently coexist leading to myocardial ischaemia. CAD, coronary artery disease.
in support of numerical equivalency between these 
indices suggesting all can be used to guide treatment 
strategy.11 Angina with underlying obstructive CAD 
allows symptom guided myocardial revascularisa-
tion (often with percutaneous coronary interven-
tion (PCI)) and is effective in reducing ischaemic 
burden and symptoms (in many patients). Recent 
studies have served evidence that functional coro-
nary disorders overlap and may contribute to 
angina even in patients with obstructive epicardial 
CAD. Dynamic changes in lesion or vessel ‘tone’ 
and propensity to vasoconstriction is important and 
may cause rest angina that is frequently overlooked 
in patients with obstructive CAD.12 During invasive 
physiological assessment of ischaemia during exer-
cise, Asrress et al showed that ischaemia developed 
at FFR averaging≈0.76 which is not often observed 
with adenosine induced hyperaemia.13 This finding 
implies there are other important drivers of suben-
docardial ischaemia (myocardial supply:demand 
factors). Furthermore, it reinforces that angina is 
not synonymous with ischaemia or flow- limiting 
coronary disease (eg, abnormal FFR or NHPR). 
Coronary anatomy and physiology should not be 
considered in isolation but in the context of the 
patient.
Angina-myocardial ischaemia discordance
Although obstructive CAD or microvascular 
dysfunction may be present, the link between isch-
aemia and angina is not clearcut. The ‘ischaemic 
threshold’ (the heart rate- blood pressure product at 
the onset of angina) has intraindividual and interin-
dividual variability.14 Innate differences in vascular 
tone and endocrine changes (eg, menopause) may 
influence propensity to vasospasm while envi-
ronmental factors including cold environmental 
temperature, exertion and mental stress are rele-
vant. The large international CLARIFY registry 
highlighted the importance of symptoms, showing 
that angina with or without concomitant ischaemia, 
was more predictive of adverse cardiac events 
compared with silent ischaemia alone.15 Other 
potential drivers of discordance between angina 
and ischaemia include variations in pain thresholds 
and cardiac innervation (eg, diabetic neuropathy).
symptoms and/or signs of ischaemia but no 
obstructive coronary artery disease (InoCa)
Cardiologists are inclined to adopt a ‘stenosis 
centric’ approach to patient management; however, 
as clinicians we must appreciate that all factors are 
relevant, including coronary anatomy and function 
but systemic health and the psychosocial back-
ground (figure 2). First, systemic factors including 
heart rate, blood pressure (and their product) and 
myocardial supply:demand ratio (Buckberg index) 
are relevant.16 Reduced myocardial oxygen supply 
from problems such as anaemia or hypoxaemia 
should always be considered.
Second, coronary factors are well recognised but 
certain nuances are overlooked. In 2018, the first 
international consensus guidelines clarify that a 
definite diagnosis of MVA may be made in patients 
with angina with no underlying obstructive CAD, 
evidence of reversible ischaemia on functional 
testing  and objective  evidence of  coronary micro-
vascular dysfunction (table 1).17 ‘Probable MVA’ 
is defined by three of the above criteria. Coro-
nary microvascular dysfunction may be structural 
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Table 1 Classification of angina by pathophysiology
angina with obstructive Cad
Obstructive CAD Flow limiting epicardial coronary artery disease*  ► >90% stenosis in a major coronary vessel
 ► Fractional flow reserve ≤0.80 or NHPR<0.90
 ► Intermediate coronary stenosis in single major vessel with documented ischaemia
symptoms and/or signs of ischaemia but no obstructive Cad (InoCa)
Microvascular 
angina†17
  1. Symptoms of myocardial ischaemia  ► Effort and/or rest angina
 ► Angina equivalents (ie, shortness of breath)
    2. Absence of obstructive CAD*  ► FFR>0.80
 ► NHPR>0.89
 ► Absence of flush ostial branch vessel occlusions
    3. Objective evidence of myocardial ischaemia  ► Ischaemic ECG changes during an episode of chest pain
 ► Stress- induced chest pain and/or ischaemic ECG changes in the presence or absence of transient/
reversible abnormal myocardial perfusion and/or wall motion abnormality
    4. Coronary microvascular dysfunction  ► Impaired CFR (≤2.0 or≤2.5 depending on methods used)
 ► Increased coronary microvascular resistance (eg, IMR>25, HMR≥2.5 mm Hg cm–1 s)
 ► Coronary microvascular spasm, defined as reproduction of symptoms, ischaemic ECG shifts but no 
epicardial spasm during acetylcholine testing.
 ► Coronary slow flow phenomenon, defined as TIMI frame count >25
Vasospastic 
angina‡42
Nitrate- responsive angina At least one of:
 ► Rest angina—especially between night and early morning
 ► Marked diurnal variation in exercise tolerance—reduced in morning
 ► Precipitated by hyperventilation
 ► Calcium channel blockers (but not β-blockers) suppress episodes
  Ischaemic ECG changes During spontaneous episode, any one of the following in at least two contiguous leads:
 ► ST segment elevation ≥0.1 mV
 ► ST segment depression ≥0.1 mV
 ► New negative U waves
  Coronary artery spasm Either spontaneously or in response to provocation (eg, acetylcholine):
 ► Transient total or subtotal coronary artery occlusion (>90% constriction)
 ► Reproduction of angina symptoms
 ► Ischaemic ECG changes
*The finding of obstructive epicardial disease does not exclude other important contributors to ischaemia (microvascular dysfunction and/or vasospasm). The physiological 
ischaemic lesion thresholds are drawn from 2018 ESC guidelines for myocardial revascularisation and randomised trials; however, the authors acknowledge that majority 
of lesions with grey- zone physiology values (eg, FFR 0.75–0.82) are not associated with downstream myocardial ischaemia (NCT02425969—Dr B Hennigan, Personal 
Correspondence).
†Definitive MVA is only diagnosed if all four criteria are present. Suspected MVA is diagnosed if criteria 1 and 2 are met but only one of the final two criteria are met (either 
objective evidence of ischaemia (criterion 3) or evidence of coronary microvascular dysfunction (criterion 4).
‡'Definitive vasospastic angina’ is diagnosed if nitrate- responsive angina is evident during spontaneous episodes and either the transient ischaemic ECG changes during the 
spontaneous episodes or coronary artery spasm criteria are fulfilled. ‘Suspected vasospastic angina’ is diagnosed if nitrate- responsive angina is evident during spontaneous 
episodes but transient ischaemic ECG changes are equivocal or unavailable and coronary artery spasm criteria are equivocal. NHPR (eg, iwFR, dPR).
CAD, coronary artery disease; CFR, coronary flow reserve; CFR, coronary flow reserve; dPR, diastolic pressure ratio; FFR, fractional flow reserve; HMR, hyperaemic microvascular 
resistance; IMR, index of microcirculatory resistance; MVA, microvascular angina; NHPR, non- hyperaemic pressure ratio.
(eg, small vessel rarefaction or increased media: 
lumen ratio) or functional (eg, endothelial impair-
ment) and these disorders may coexist. Other coro-
nary causes of INOCA include intramyocardial 
‘tunnelled’ segments of epicardial arteries (myocar-
dial ‘bridging’) who may have ischaemia on exer-
cise. These segments are particularly susceptible to 
vasoconstriction due to endothelial impairment.18 
Coronary arteriovenous malformations are rare but 
may also cause of myocardial ischaemia. Vasospastic 
angina (‘Prinzmetal’s angina’) is typically described 
as recurrent rest angina with focal occlusive prox-
imal epicardial often seen in young smokers with 
characteristic episodic ST segment elevation during 
attacks. Notably, the more common form of VSA is 
distal and diffuse subtotal epicardial vasospasm and 
is characterised by ST segment depression and may 
occur during exertion. Typical cardiac risk factors 
and endothelial impairment may be implicated.19
The long- term (sometimes lifelong) burden of 
MVA and/or VSA on physical and mental well- being 
can be profound. Patients with these conditions 
commonly attend primary care and are repeat-
edly hospitalised with acute coronary syndromes, 
arrhythmias and heart failure driving up health 
resource utilisation, morbidity and reducing quality 
of life.20 21
The third and final group of factors that drive 
ischaemia in patients with angina but without 
obstructive CAD include cardiac factors. These 
include left ventricular hypertrophy or restrictive 
cardiomyopathy where subendocardial ischaemia 
results impaired perfusion from arterioles pene-
trating deeper into myocardial tissue with shorter 
diastole, enhanced systolic myocardial vessel 
constriction and enhanced interstitial matrix.22 
Heart  failure  (with  reduced  or  preserved  ejec-
tion fraction) can lead to elevated left ventricular 
end diastolic pressure which reduces the diastolic 
myocardial perfusion gradient. Valvular heart 
disease (eg, aortic stenosis (AS)) is an important 
consideration in patients with INOCA. In AS, most 
experts support haemodynamic factors as the main 
cause of ischaemia, especially since symptoms and 
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figure 2 Contributing factors to myocardial ischaemia. The contributors to the physiological myocardial perfusion gradient and resultant ischaemia 
can be broken down at patient- level into systemic, cardiac and coronary factors. CAD, coronary artery disease; SEVR, subendocardial viability 
ratio.<Modified with permission from 47>.
coronary flow reserve (CFR) improve immediately 
after valve replacement.23 Patients with INOCA 
may have increased painful sensitivity to innocuous 
cardiac stimuli (eg, radiographic contrast) without 
inducible ischaemia. Furthermore, some affected 
patients have a lower pain threshold and tolerance 
to the algogenic effects of adenosine (thought to 
be the main effector of ischaemia mediated chest 
pain).24
Gender differences and angina presentation
The WISE (Women’s Ischemia Syndrome Evalua-
tion) study highlighted that over 2/3 of women with 
angina had no obstructive CAD and the majority of 
these had functional impairments in the coronary 
microcirculation associated with significant impair-
ments in health- related quality of life.25 Indeed, 
women have more non- obstructive CAD and func-
tional IHD which are frequently overlooked and 
hence undertreated.26 27 Over time and at different 
ages, women have a similar or slightly higher prev-
alence of angina than men across countries inde-
pendent of diagnostic and treatment practices.28 
Different patterns of IHD may be anticipated to 
cause different angina symptoms between genders. 
Nonetheless, recent evidence moves the field away 
from the ‘male- typical, female- atypical’ model 
of angina towards a ‘gender continuum’ whereby 
the  objective  reports  between  men  and  women’s 
symptoms are more similar than treating physi-
cians perceive. Interestingly, dyspnoea was a feature 
in around ¾ of angina presentations without any 
significant difference between the sexes.29
assEssmEnT: CurrEnT guIdELInEs
Assessment strategies in current major international 
guidelines focus on the detection of underlying 
obstructive CAD. European and American guide-
lines (ESC and ACC/AHA, respectively) favour a 
Bayesian approach whereby overall probability of 
obstructive CAD after testing is determined from 
pretest probability modified by the diagnostic test 
results. The ACC/AHA guidelines determine pretest 
risk from a modified Diamond Forrester model,30 
whereas the Europeans favour the CADC (Coro-
nary Artery Disease Consortium) model which 
avoids overestimation seen with Diamond- Forrester 
and appears a more accurate assessment of pretest 
risk.31 Both current guidelines stratify pretest risk 
into low, intermediate or high groups with use of 
non- invasive testing suggested in the intermediate 
group (ACC/AHA arbitrarily defined as 10%–90% 
or 15%–85% in ESC).
In stark contrast, the NICE CG95 2016 update 
‘chest pain of recent onset: assessment and diag-
nosis’ discarded the Bayesian pretest risk assess-
ment. NICE advocates first- line multidetector 
CT coronary angiography (CTCA) in all patients 
with typical or atypical chest pain (box 1), those 
whose history does not suggest angina but who 
have ST changes or Q waves on a resting ECG.32 
Functional testing (eg, exercise stress echo or stress 
perfusion magnetic resonance—CMR) are rele-
gated to second- line if CTCA is non- diagnostic or 
the clinical significance of known CAD needs clar-
ified. Potential benefits of this approach include 
a much higher diagnostic accuracy for detection 
of atherosclerotic heart disease than functional 
testing which potentially carries the best long- term 
prognostic information for patients with CAD.27 
Extended 5- year outcomes from SCOTHEART 
showed a reduction in the combined endpoint of 
death from coronary heart disease or non- fatal 
myocardial infarction among the group randomised 
to CTCA compared with standard care (2.3% vs 
3.9%; absolute risk reduction (ARR) 1.6% number 
needed to treat (NNT) 63). This effect was driven 
by better targeting of preventative therapies. The 
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authors report that although overall prescriptions 
of preventive cardiovascular medications were only 
modestly increased (~10% higher) in the CTCA 
arm, changes in such therapies occurred in around 
one in four patients allowing more personalised 
treatment to patients with most coronary atheroma 
in the CT group.
These results should be considered in relation 
to design limitations of this trial. There was no 
control procedure (test vs no test), the threshold 
for prescribing preventive therapy with statins was 
20%–30% likelihood of a CHD event in 10 years 
(much higher than many contemporary healthcare 
systems), CTCA was performed on top of tread-
mill exercise testing which has poor test accuracy 
in distinct patient groups, notably women, and 
the procedures were unblinded and open- label. 
Outcome reporting that is narrowly focused on 
CHD does not take account of other cardiovas-
cular events, such as hospitalisation for arrhyth-
mias and heart failure, which have implications 
for quality of life. In PROMISE, a ‘head- to- head’ 
trial of CTCA versus functional testing, there were 
no differences in health outcomes.33 In the inter-
ests of providing patients and clinicians with a 
reliable and accurate test result, a strategy based 
on anatomical CTCA has fundamental limita-
tions. SCOT- HEART identified that obstructive 
CAD affects the minority (one in four) patients 
presenting to the Chest Pain Clinic with known or 
suspected angina. This means that an anatomical 
test strategy with CTCA leaving the aetiology and 
treatment unexplained in the majority of affected 
patients, which becomes all the more relevant 
considering that anginal symptoms and quality of 
life are worse when CTCA is used.34 Diagnostic 
options are enhanced by advances in technology 
and tests for the functional significance of CAD 
are now feasible, but at significant cost.35 NICE 
guidelines state that HeartFlow FFRCT should be 
considered as an ‘option for patients with stable, 
recent onset chest pain who are offered CCTA as 
part of the NICE pathway on chest pain’. Using 
HeartFlow FFRCT may avoid the need for inva-
sive coronary angiography and revascularisation; 
however,  major  randomised  controlled  trials  are 
ongoing (eg, FORECAST study NCT03187639).
We support efforts to provide a definitive diag-
nosis for patients with ongoing angina symptoms 
after a ‘negative’ CTCA, initially using non- invasive 
ischaemia testing. Notably, the recent International 
Standardised Criteria for diagnosing ‘suspected’ 
MVA would be met in patients with symptoms 
of myocardial ischaemia, no obstructive CAD 
and  objective  evidence  of  myocardial  ischaemia 
(table 1). Invasive testing for diagnosis of MVA 
could be reserved for subjects with refractory symp-
toms and negative ischaemia testing or diagnostic 
uncertainty. The criteria for ‘definite MVA’ require 
the above AND objective evidence of microvascular 
dysfunction (eg, reduced CFR or raised microvas-
cular resistance).
Limitations of current guidelines
There are limitations to the current NICE-95 guide-
line, not least the logistics and cost of service provi-
sion with an estimated 700% increase in cardiac 
CT required across the UK.36 Importantly, what do 
we report to the majority of patients with anginal 
chest pain but no obstructive CAD on the CTCA? 
In fact, only 25% of patients had obstructive CAD 
and at 6 weeks based on the CTCA findings, 66% 
of patients were categorised as not having angina 
due to coronary heart disease. The possibility 
of false reassurance for the patients with angina 
and INOCA is an open question and may be one 
contributing factor for the lack of improvement in 
angina and quality of life in the CTCA group vs 
standard care.34 We must strive to deliver patient- 
centred care, recognising that most patients seek 
explanation for their symptoms in combination 
with effective treatment options.37 CTCA is an 
insensitive test for disorders of coronary vascular 
function, which may affect the majority of patients 
attending with anginal symptoms. Since the majority 
of affected patients have no obstructive CAD, and 
the  majority  of  them  are  women,  an  anatomical 
strategy introduces a sex- bias into clinical practice, 
whereby a positive test result (obstructive CAD) 
is more likely to occur in men and a positive test 
for small vessel disease is less likely to occur in 
women. Furthermore, patient- reported outcomes 
including angina limitation, frequency and overall 
quality of life improve less after CTCA compared 
with standard care, notably in patients with no 
obstructive CAD.34 Non- invasive functional testing 
with positron emission tomography (PET), echo 
and most recently stress perfusion CMR has diag-
nostic value for stratified medicine. Finally, strati-
fication of patients using luminal stenosis severity 
on angiography overlooks the spectrum of risk 
associated with overall plaque burden and may miss 
functional consequences associated with diffuse but 
angiographically mild disease (particularly when 
subtending large myocardial mass).
Non- invasive functional testing includes myocar-
dial perfusion scintigraphy, exercise treadmill testing 
(including stress echocardiography) or contrast- 
enhanced stress perfusion MRI depending on local 
availability. Novel pixel- wise absolute perfusion 
quantification of myocardial perfusion by CMR 
will likely improve the efficiency of absolute quan-
tification of myocardial blood flow by CMR.38 PET 
is the reference- standard non- invasive assessment of 
myocardial blood flow permitting quantitative flow 
derivation in mL/g/min. Clinically, PET- derived 
quantification of myocardial blood flow (MBF) 
can assist in the diagnosis of diffuse epicardial or 
microvascular disease; however, limitations include 
poor availability and exposure to ionising radiation. 
Non- invasive workup often provides important 
insights on coronary microvascular function and 
are reviewed in detail elsewhere.39
With functional testing relegated to second- line 
testing, clinicians may forgo additional tests after 
a negative CTCA particularly in an era of fiscal 
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restraint and if patients’ symptoms are viewed as 
atypical. One important group that will be dispa-
rately affected by an ‘anatomy first’ strategy are 
women—over half of all patients with suspected 
angina in the large prospective trials of CTCA are 
female. While the benefits of CTCA to diagnose 
CHD and prevent CHD events are similar in women 
and men, the large majority of patients undergoing 
CTCA do not have obstructive CAD potentially 
leading to misdiagnosis and suboptimal manage-
ment in patients with INOCA.33 Women, are most 
likely to have no obstructive CAD and their cardiac 
risk is associated with severely impaired CFR and 
not obstructive CAD.40 Overall, there is growing 
awareness of sex- specific differences in coronary 
pathophysiology and potential for different patterns 
of CAD in women. This is a rapidly evolving fertile 
area for further research.
Invasive coronary angiography and physiological 
assessment
UK NICE guidelines suggest that invasive coronary 
angiography is a third- line investigation for angina 
when the results of non- invasive functional imaging 
are inconclusive. Patients with typical symptoms, 
particularly those in older age groups with higher 
probability of non- diagnostic CTCA scans, often 
proceed directly to invasive coronary angiography. 
During cardiac catheterisation, assuming that 
epicardial CAD is responsible for their symptoms, 
visual assessment for severe angiographic stenosis 
(>90%)  is  sufficient  to  establish  significance  and 
treatment plan for these patients. Two common 
pitfalls for visual interpretation of angiograms 
were recently highlighted by two coronary phys-
iology pioneers Gould and Johnson. Using their 
quantitative myocardial perfusion database of over 
5900 patients showing that occult coronary diffuse 
obstructive coronary disease or flush ostial stenosis 
may be both be overlooked on angiography and 
mislabelled as microvascular angina with subop-
timal treatment.41 The ischaemic potential of inde-
terminate coronary lesions (~40%–70% diameter 
stenosis) is best assessed using pressure- derived 
indices, such as FFR, and non- hyperaemic pressure 
ratios (NHPR: dPR, nstantaenous wave free ratio 
(iwFR) and others) to guide revascularisation deci-
sions. However, as is the case with coronary angi-
ography, these indices do not inform the clinician 
about disorders of coronary artery vasomotion.
Invasive tests of coronary artery function are the 
reference standard for the diagnosis of coronary 
microvascular dysfunction17 and vasospastic angina 
(table 1; figure 1).42 Coronary microvascular resis-
tance may be directly measured using guidewire- 
based physiological assessment during adenosine 
induced hyperaemia. Methods to assess this include 
using a pressure- temperature sensitive guidewire 
by thermodilution (index of microcirculatory resis-
tance; IMR) or Doppler ‘ComboWire’ (hyperaemic 
microvascular resistance; HMR). These metrics 
have been the focus of a recent review article in 
Heart.43 There are several other haemodynamic 
indices of microvascular function including instan-
taneous hyperaemic diastolic pressure velocity 
slope, wave intensity analysis and zero flow pres-
sure. A detailed description of these parameters 
is out with the scope of this review.41 Elevated 
coronary microvascular  resistance  (eg,  IMR >25) 
carries prognostic utility in patients with reduced 
CFR but unobstructed arteries. Lee et al found over 
fivefold higher risk of adverse cardiac events in 
these subjects compared with controls with normal 
microvascular function.44
CFR is the ratio of maximum hyperaemic blood 
flow to resting flow. CFR in the absence of obstruc-
tive CAD can signify impaired microvascular dila-
tion. Lance Gould first introduced this concept 
almost 50 years ago but more recently proposed 
that CFR should be considered in the context of the 
patient and the hyperaemic flow rate.41 The abso-
lute threshold for abnormal CFR varies depending 
on the method of assessment, the patient popu-
lation studies and the controversy reflects the 
dichotomous consideration of the continuous 
physiological spectrum of ischaemia. Abnormal 
CFR thresholds vary from ≤2.0 or ≤2.5 with more 
restrictive criteria for abnormal CFR (<1.6) being 
more specific for myocardial ischaemia and worse 
outcomes but at the cost of reduced sensitivity. On 
the other hand, studies of transthoracic Doppler 
derived CFR (which has less reproducibility) often 
use cut- offs of 2.5 with some observational evidence 
of worse outcomes in the INOCA population with 
CFR below this threshold.45 The influence of rate- 
pressure product on resting flow and its correction 
for CFR determination should be considered.
Systolic endocardial viability ratio (SEVR) is a 
ratio of myocardial oxygen supply:demand derived 
from the aortic pressure- time integral (diasto-
le:systole). However, it is well known that blood 
pressure, pulse and SEVR perturbations influence 
CFR more closely than microcirculatory resis-
tance. Reduced CFR without raised microvascular 
resistance still portends increased cardiovascular 
risk44 and may be a distinct subgroup with different 
drivers of ischaemia (eg, abnormal supply:demand 
systemic haemodynamic factors; figure 2). Alterna-
tively, these patients may be at an earlier stage of 
disease prior to more established structural micro-
vascular damage. Sezer et al showed the pattern 
of coronary microvascular dysfunction early in 
type II diabetes was driven by disturbed coronary 
regulation and high resting flow.46 In longstanding 
diabetes however, elevated microvascular resis-
tance was observed reflecting established struc-
tural microvascular disease. This process matches 
the paradox of microvascular disease in diabetic 
nephropathy where increased glomerular filtration 
rate (GFR) typifies the early stages of disease prior 
to later structural damage and reduction in GFR.
The third mechanism of microvascular dysfunc-
tion is inappropriate propensity to vasoconstric-
tion of the small coronary arteries, typically this is 
assessed using intracoronary acetylcholine infusions 
as a pharmacological probe.
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Rationale and benefit of invasive coronary function 
testing in INOCA
We contend that a complete diagnostic evaluation 
of the coronary circulation should assess struc-
tural and functional pathology.47 The British Heart 
Foundation CorMicA trial provides evidence about 
the opportunity to provide a specific diagnosis to 
patients with angina using an interventional diag-
nostic procedure (IDP) when obstructive CAD 
is excluded by invasive coronary angiography. 
Consenting patients were randomised 1:1 to the 
intervention group (stratified medical therapy, IDP 
disclosed) or the control group (standard care, IDP 
sham procedure, results not disclosed). The diag-
nostic intervention included pressure guidewire- 
based assessment of FFR, CFR and IMR during 
adenosine induced hyperaemia (140 µg/kg/min). 
Vasoreactivity testing was performed by infusing 
incremental concentrations of acetylcholine (ACh) 
followed by a bolus vasospasm provocation (up to 
100 µg). The diagnosis of a clinical endotype (micro-
vascular angina, vasospastic angina, both, none) was 
linked to guideline- based management. The primary 
endpoint was the mean difference in angina severity 
at 6 months (as assessed by the Seattle Angina 
Questionnaire summary score—SAQSS) which was 
analysed using a regression model incorporating 
baseline score. A total of 391 patients were enrolled 
between 25/11/2016 and 11/12/2017. Coronary 
angiography revealed obstructive disease in 206 
(53.7%). One hundred and fifty- one (39%) patients 
without angiographically obstructive CAD were 
randomised. The underlying abnormalities revealed 
by the IDP included: isolated microvascular angina 
in 78 (51.7%), isolated vasospastic angina in 25 
(16.6%), mixed (both) in 31 (20.5%) and non- 
cardiac chest pain in 17 (11.3%). The intervention 
was associated with a mean improvement of 11.7 
units in the SAQSS at 6 months (95% CI 5.0 to 
18.4; p=0.001). In addition, the intervention led 
to improvements in the quality of life (EQ5D index 
0.10 units; 0.01 to 0.18; p=0.024). After disclo-
sure of the IDP result, over half of treating clini-
cians changed their diagnosis about the aetiology of 
their patients’ symptoms. There were no procedural 
serious adverse events and no differences in major 
adverse cardiac events (MACE) at 6 months. Inter-
estingly, there were sustained quality of life benefits 
at one year for INOCA patients helped by correct 
diagnosis and linked treatment started at the index 
invasive procedure.48 Future trials are anticipated 
to determine the wider external validity of this 
approach.
managEmEnT
Medical therapy to prevent new vascular events 
should be considered and these include consider-
ation of aspirin, ACE inhibitors (ACEi) and statins. 
The latter two agents have pleiotropic properties 
including beneficial effects on endothelial function 
and so may be helpful in treating coronary micro-
vascular dysfunction. Sublingual glyceryl trinitrate 
tablets or spray should be used for the immediate 
relief of angina and before performing activities 
known to bring on angina.
non-pharmacological
As with many cardiovascular diseases, lifestyle 
modification including risk factor control and 
patient education are key. Lifestyle recommenda-
tions are covered in detail in recent ESC guidelines. 
The adverse effect of angina on patient well- being 
and quality of life can be substantial. It is crucial 
that we assess for this and manage appropriately. 
After diagnosis with angina, cardiac rehabilitation 
can be useful to educate and build confidence. One 
useful patient led education aid is called the ‘Angina 
plan’. This tool is a workbook and relaxation plan 
delivered in primary care, which helps improve 
angina symptoms (frequency and limitation) while 
reducing anxiety and depression.49 The ORBITA 
trial highlights the benefits of placebo effect and 
we support that the positive diagnosis may be 
therapeutic in itself. Angina symptoms are often 
subjective  and  multifactorial  in  origin,  so  patient 
education and validation of symptoms may facili-
tate further improvement.
management: non-obstructive Cad
Generic guidelines on angina management 
frequently overlooks the precision medicine goal 
whereby treatment is targeted to underlying patho-
physiology. There is a lack of high- quality clinical 
trial data for treating microcirculatory dysfunc-
tion. The current article thus proposes a reasoned 
approach to management based on evaluation of 
pathophysiological mechanisms.
We contest that angina and INOCA are syndromes 
and not a precise diagnosis (akin to myocardial 
infarction with no obstructive CAD—MINOCA). 
As such, by stratifying treatment according to 
underlying pathophysiology, we may realise better 
outcomes for our patients.
Impaired coronary vasodilator capacity (reduced CFR)
Bairey Merz et al performed a randomised 
controlled trial of ranolazine in the WISE popula-
tion. Notably, there was no net benefit effect on the 
INOCA population as a whole; however, in patients 
with reduced CFR (<2.5), there was a benefit 
suggestion of improved myocardial perfusion 
reserve index (MPRi) after established treatment.50 
Lanza and Crea highlight that subjects with reduced 
CFR might preferentially be treated with drugs that 
reduce myocardial oxygen consumption (eg, beta- 
blockers (BB)—for example, Nebivolol 1.25–10 mg 
daily).51 There is accumulating evidence that long 
acting nitrates are ineffective or even detrimental 
in MVA. Lack of efficacy may relate to poor tolera-
bility, steal syndromes through regions of adequately 
perfused myocardium and/or related to the reduced 
responsiveness of nitrates within the coronary 
microcirculation.52 Furthermore, chronic therapy 
with nitrate may induce endothelial dysfunction 
and oxidative stress, predominantly via endothelin 
dependent pathways.53
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Increased microvascular constriction (structurally 
increased microvascular resistance or functional 
propensity to microvascular spasm)
Subjects with increased microvascular vasoconstric-
tion may be treated with vasodilator therapies acting 
on the microcirculation. These include calcium 
channel blockers (CCB—for example, amlodipine 
2.5–10 mg daily) or nicorandil (eg, 5–30 mg two 
times a day). Hyper- reactivity to constrictor stimuli 
resulting in propensity to microvascular spasm may 
be provoked by endothelial dysfunction. This was 
first described my Mohri et al over three decades 
ago with recent physiological studies suggesting 
treatment aimed at improving endothelial func-
tion (eg, ACEi, Ramipril 2.5–10 mg) may improve 
the microvascular tone and/or the susceptibility 
to inappropriate spasm.54 55 A detailed discussion 
of all potentially therapeutic options for coronary 
microvascular dysfunction is beyond the scope of 
this article; however, a systematic review by Mari-
nescu et al may be of interest to readers wishing 
further information.56
Epicardial spasm (vasospastic angina)
The poor nitrate response or tolerance seen in MVA 
contrasts with patients with vasospastic angina, in 
Table 2 Angina pharmacotherapy
Treatment angina type Example Investigation mechanism of action Common side- effects
ß-blockers MVA, CAD Bisoprolol: 1.25–10 mg Reduced CFR and/or 
structural microvascular 
dysfunction (raised 
microvascular resistance)
Reduction in myocardial oxygen 
consumption
Fatigue, blurred vision,
cold hands
Calcium channel 
antagonists
All Dihydropyridine (amlodipine: 
2.5–10 mg daily)
Non- dihydropyridine 
(verapamil: 40–240 or 
diltiazem up to 500 mg; 
controlled release)
Propensity to coronary 
vasospasm (epicardial 
and/or microvascular)
↓ spontaneous and inducible coronary 
spasm via vascular smooth muscle 
relaxation and ↓ oxygen demand
Vascular smooth muscle relaxation, 
reduction in myocardial oxygen 
consumption
Constipation, ankle swelling, 
flushing
Vasodilators           
  Nitrates CAD, VSA Isosorbid mononitrate: 
30–120 mg one time a day 
(controlled released)
Propensity to epicardial 
coronary vasospasm
↓ spontaneous and inducible coronary 
spasm via large epicardial vasodilation, 
↓ oxygen demand. Lack of efficacy in 
microvascular angina with potential 
deleterious effect
Headaches, dizziness, flushing
  Nicorandil All Nicorandil: 5–30 mg two 
times a day
All Potassium channel activator with coronary 
microvascular dilatory effect
Dizziness, flushing, weakness, 
nausea
  Rho kinase inhibitors VSA, CMD Fasudil: 5–20 mg; three 
times a day
Epicardial and/or 
microvascular vasospasm
Reduce calcium sensitisation of vascular 
smooth muscle, maintains coronary 
vasodilation
Rashes, flushing, hypotension
Late Na+Current 
Inhibitors
MVA, CAD Ranolazine: 375–500 mg 
two times a day
Reduced CFR Improves MPRi in patients with MVA and 
reduced CFR
Nausea, dizziness, headache
If channel blockers CAD, MVA Ivabradine: 2.5–7.5 mg two 
times a day
All Ivabradine has shown anti- ischaemic and 
antianginal activity
Bradycardia, AF, headache
Partial fatty- acid 
oxidation inhibitors
CAD, MVA Perhexiline: 50–400 mg daily 
or Trimetazidine
Plasma concentration 
required for dose titration.
Perhexiline Inhibits carnitine O- 
palmitoyltransferase 1 and 2, which 
transfer free fatty acid from the cytosol 
into mitochondria.
Dizziness, unsteady, nausea 
and vomiting
Improved endothelial function/pleiotropic
  
      
  ACE inhibitors MVA, CAD Ramipril: 2.5–10 mg daily Hyper- reactivity to stimuli 
(eg, acetylcholine, exercise, 
stress)
Improve CFR, reduce workload, may 
improve small vessel remodelling. 
Improves endothelial vasomotor 
dysfunction
Cough, renal impairment, 
hyperkalaemia
  Statins All Atorvastatin: 10–80 mg daily
Rosuvastatin: 5–40 mg daily
All Improved coronary endothelial function 
reduced vascular inflammation
Myalgia, headache, cramps
  Hormone- replacement 
therapy*
MVA Oestradiol: 1 mg daily Angina in early 
menopause
Oestrogen therapy improves endothelial 
function short- term in CMD
↑ Risk of breast cancer, 
marginally ↑ risk of CVD
Tricyclic antidepressants 
(TCA)
MVA with 
abnormal pain 
processing
Amitriptyline: 5–10 mg 
nocte
Imipramine: 10–200 mg 
daily
All Counteracts enhanced nociception. 
Thought to exert an analgesic effect on 
the visceral component associated with 
cardiac pain.
  Blurred vision, dry mouth, 
drowsiness, impaired 
coordination
Non- pharmacological All Smoking cessation, Exercise, 
cardiac rehabilitation, 
Mediterranean diet, 
cognitive behavioural 
therapy, weight loss, Yoga
Metabolic syndrome, 
endothelial dysfunction, 
cardiovascular risk factors, 
anxiety/depression
  Adjunctive non- 
pharmacological interventions
*May be helpful in some postmenopausal women. More information on experimentary pharmacotherapy in refractory angina can be found in review by Henry et al.62
CAD, angina with obstructive coronary artery disease; MPRi, myocardial perfusion reserve index; MVA, microvascular angina; VSA, vasospastic angina.
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whom nitrates are a cornerstone of therapy and 
BB are relatively contraindicated.7 Dual patholo-
gies (VSA with underlying microvascular disease) is 
increasingly recognised. A diagnosis of VSA facili-
tates treatment using non- dihydropiridine calcium 
antagonists (eg, diltiazem- controlled release up to 
500 mg daily). Overall, CCB are effective in treating 
over 90% of patients.57 High doses of calcium 
antagonists (non- dihydropiridine and dihydropyr-
idine) may be required either alone or in combi-
nation. Unfortunately, ankle swelling, constipation 
and other side effects may render some patients 
intolerant. In these cases, long- term nitrates may be 
used with good efficacy in this group. In about 10% 
of cases, coronary artery spasm may be refractory to 
optimal vasodilator therapy. Japanese VSA registry 
data shows nitrates were not associated with MACE 
reduction in VSA, and importantly when added to 
Nicorandil were potentially associated with higher 
rates of adverse cardiac events.58 Alpha blockers 
(eg, clonidine) may be helpful in selected patients 
with persistent vasospasm. In patients with poor 
nitrate tolerance the K+-channel opener nicorandil 
(5–10 mg two times a day) can be tried. Consider 
secondary causes in refractory VSA (eg, coronary 
vasculitis) and in selected patients with ACS presen-
tations, coronary angioplasty may be considered as 
a bailout option.
management: obstructive Cad
Pharmacological
Although NICE guidelines offer either BB or CCB 
first line, although we support BB initially because 
they are generally better tolerated (table 2).59 Long- 
term evidence of efficacy is limited between BB 
and CCB and there are no proven safety concerns 
favouring one or the other. Dihydropyridine calcium 
may be added to BB if blood pressure permits. 
NICE CG126 states third line options can be either 
added on (or substituted if BB/CCB not tolerated). 
These include nitrates (eg, isosorbide mononitrate 
30–120 mg controlled release), ivabradine (eg, 
2.5–7.5 mg two times a day), nicorandil (5–30 mg 
two times a day) or ranolazine (375–500 mg two 
times a day). These are all third line medications 
that can be used based and combined with BB and/
or CCB depending on comorbidities, contraindica-
tions, patient preference and drug costs (figure 3). 
The RIVER- PCI study found that anti- ischaemic 
pharmacotherapy with ranolazine did not improve 
the prognosis of patients with incomplete revas-
cularisation after percutaneous coronary inter-
vention.60 This was a reminder that alleviation of 
ischaemia may not improve ‘hard’ endpoints in 
patients with chronic coronary syndromes but helps 
us to remain focused on improving their quality of 
life.
Revascularisation
Recently revised 2018 ESC guidelines suggest 
that myocardial revascularisation is indicated 
to improve symptoms in haemodynamically 
significant coronary stenosis with insufficient 
response to optimised medical therapy. Patients’ 
wishes should be accounted for in relation 
to the intensity of antianginal therapy as PCI 
can offer patients with angina and obstructive 
CAD a reduced burden from polypharmacy. 
Angina persists or recurs in more than one in 
five patients following PCI and microvascular 
dysfunction may be relevant. Guidelines support 
consideration of revascularisation for prognosis 
in asymptomatic ischaemia in patients with large 
ischaemic burden (left main/proximal left ante-
rior  descending  artery  stenosis >50%)  or  two/
three vessel disease in patients with presumed 
ischaemia cardiomyopathy (LVEF<35%).
Refractory angina is common in patients with 
complex CAD including those with previous 
coronary artery bypass grafting (CABG) and 
chronic total occlusions (CTOs). Over the last 
decade, vast strides in technique, training and 
tools  have  delivered  major  increases  in  the 
success of CTO PCI. These angina patients often 
figure 3 Empirical pharmacological treatments for patients with angina. ACEi, Angiotensin converting enzyme inhibitor; ASP, aspirin; BB, beta- 
blocker; Endo, endothelial; IVA, ivabradine; MVA, microvascular angina; NIC, nicorandil; NIT, nitrate; Obs CAD, obstructive coronary artery disease;, 
RAN, ranolazine; RF, risk factor.
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have incomplete revascularisation with lesions 
or anatomy previously considered ‘unsuitable 
for intervention’ but now amenable to treatment 
by trained operators. A recent review article in 
Heart summarises non- pharmacological ther-
apeutic approaches to patients with refractory 
angina including cognitive behavioural therapy 
(CBT), stellate ganglion nerve blockade, Trans-
cutaneous Electrical Nerve Stimulation (TENS)/
spinal cord stimulation and pain modulating 
antidepressants (eg, imipramine).61 Of note, 
coronary sinus reducers deployed using a tran-
scatheter venous system have shown early 
promise in clinical studies.
future directions
Based on test accuracy, health and economic bene-
fits, non- invasive and invasive functional tests 
should be considered a standard of care in patients 
with known or suspected angina, especially if 
obstructive CAD has been excluded by CT or inva-
sive coronary angiography. Computational fluid 
dynamic modelling of the functional significance of 
CAD, notably with FFRct, is an emerging option 
and clinical trials, including FORECAST ( Clinical-
Trials. gov Identifier: NCT03187639) and PRECISE 
(NCT03702244), are ongoing. The use of compu-
tational modelling as a diagnostic tool in patients 
with microvascular angina or coronary vasomotion 
disorders remains to be determined.
Systemic vascular abnormalities were recently 
highlighted in patients with INOCA potentially 
supporting a therapeutic role for targeted vascular 
therapy, for example, using selective endothelin- A 
receptor antagonists.19 The MRC Framework for 
Stratified Medicine is applicable to patients with 
angina and we believe genetic testing with precision 
medicine holds future promise.
ConCLusIon
The optimal management of patients with known 
or suspected angina begins with establishing the 
correct diagnosis.Around one half of angina patients 
have no obstructive coronary disease; many of these 
patients have microvascular and/or vasospastic 
angina.Non- invasive assessment with CTCA is a 
sensitive anatomical test for plaque which assists 
in initial treatment and risk stratification. Anatom-
ical imaging has fundamental limitations to rule 
in or rule out coronary vasomotion disorders in 
patients with symptoms and/or signs of ischaemia 
but no obstructive CAD (INOCA). Women are 
disproportionately represented in this group with 
MVA and/or VSA, the two most common causes 
of diagnoses. A personalised approach to invasive 
diagnostic testing permits a diagnosis to be made 
(or excluded) during the patients’ index presenta-
tion. This approach helps stratify medical therapy 
leading to improved patient health and quality of 
life. Physician appraisal of ischaemic heart disease 
(IHD) should consider all pathophysiology relevant 
to symptoms, prognosis and treatment to improve 
health outcomes for our patients. More research is 
warranted, particularly to develop disease modi-
fying therapy.
EsC curriculum: stable Cad
 ► Precipitants of angina.
 ► Prognosis of chronic IHD.
 ► Clinical assessment of known or suspected 
chronic IHD.
 ► Indications for, and information derived from, 
diagnostic procedures including ECG, stress 
test in its different modalities (with or without 
imaging, exercise and stress drugs) and coro-
nary angiography.
 ► Management of chronic IHD, including lifestyle 
measures and pharmacological management.
 ► Indications for coronary revascularisation 
including PCI/stenting and CABG.
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Key points
 ► Angina pectoris is a clinical syndrome occurring in patients with or without 
obstructive epicardial coronary artery disease.
 ► Diagnostic testing in angina is symptom driven and so should provide 
patients and their physicians with an explanation for their symptoms and 
used to stratify management and offer prognostic insights.
 ► Microvascular and/or vasospastic angina are common disorders of coronary 
artery function that may be overlooked by anatomical coronary testing, 
leading to false reassurance and adverse prognostic implications.
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